BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32948680)

  • 1. Clinical Utility of
    Das JP; Vargas HA; Ghafoor S; Goh AC; Ulaner GA
    J Nucl Med; 2021 May; 62(5):643-647. PubMed ID: 32948680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
    Stokkel LE; Stokkel MPM; Donswijk ML; Lahaye MJ; Bekers EM; van Rhijn BWG; Mertens LS
    Clin Genitourin Cancer; 2021 Oct; 19(5):373-380. PubMed ID: 33858788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed
    Xu L; Shi Y; Wang Y; Zhou X; Huang G; Chen R; Liu J
    Contrast Media Mol Imaging; 2020; 2020():3216179. PubMed ID: 33013244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging
    Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
    Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
    Nayak B; Dogra PN; Naswa N; Kumar R
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of
    Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
    BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
    BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Ulaner GA; Juarez J; Riedl CC; Goldman DA
    J Nucl Med; 2019 Apr; 60(4):472-477. PubMed ID: 30237211
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic Lymph Node Staging by Combined
    Pichler R; De Zordo T; Fritz J; Kroiss A; Aigner F; Heidegger I; Virgolini I; Horninger W; Uprimny C
    Clin Genitourin Cancer; 2017 Jun; 15(3):e387-e395. PubMed ID: 27601364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of
    Civelek AC; Niglio SA; Malayeri AA; Lin J; Gurram S; Chalfin HJ; Turkbey B; Valera V; Steinberg SM; Apolo AB
    Urol Oncol; 2021 Nov; 39(11):787.e17-787.e21. PubMed ID: 34140245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma?
    Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D
    Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of IV contrast enhanced
    Gündoğan C; Tatar G; Erkan E; Çakır MS; Forouz A; Toktaş MG; Çermik TF
    Hell J Nucl Med; 2021; 24(1):75-82. PubMed ID: 33928269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare case of urachal mucinous adenocarcinoma detected by 18F-FDG PET/CT.
    Li X; Liu S; Yao S; Wang M
    Clin Nucl Med; 2015 Mar; 40(3):282-5. PubMed ID: 25608160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routinely staging gastric cancer with
    Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
    Uttam M; Pravin N; Anish B; Nandita K; Arup M
    Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.